Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
6/11/2020
1
Rectal Cancer-From A to NAPRC
June 11, 2020
Presented by Christi Cox, CTR-Manager of Education
Confidential and proprietary. © ERS 2020. All rights reserved.
Confidential Information and Disclaimer
• The information provided in this presentation and accompanying documentation is confidential and proprietary and may not be reproduced or distributed without the express consent of Electronic Registry Systems, Inc. © Copyright 2020. Unauthorized use may violate copyright and trademark laws.
• The information provided in this presentation is done as a service to ERS clients. The objective of the information provided is to provide information about Rectal Cancer Care and how to collect and report data in a manner that supports your cancer program and NAPRC accreditation goals and is not intended to be a webinar on coding rules.
• At the time this presentation was created, the links provided were the most current links from various standard setters and manuals. It is ultimately the client’s responsibility to ensure the use of the proper resources for coding.
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
2
Having Trouble Hearing Me?
• If you are listening through your computer speakers, please turn up the volume on your computer. If that does not work, please dial in on the telephone.
• If you are listening through the telephone, crank up the volume on your phone, or if that does not work try listening through your speakers.
Confidential and proprietary. © ERS 2020. All rights reserved.
Housekeeping
• Handouts were distributed to the email address you provided for registration prior to this meeting.
• Handouts are also available during this webinar. They are located under the handouts pane. Just click and download.
• The webinar will be approximately 1 hour in length.
• CE Certificates will be sent later this week to the email address you provided during registration for this webinar.
Confidential and proprietary. © ERS 2019. All rights reserved.
6/11/2020
3
Objectives
• To familiarize participants with clinical aspects of Rectal Cancer including customary diagnostics, surgeries and other treatment modalities
• To explore anatomy related to rectal surgery recommendations from Operative Standards for Cancer Care
• To highlight data collection enhancements for NAPRC accreditation efforts
Confidential and proprietary. © ERS 2020. All rights reserved.
Rectal Cancer- History and Trends
Difficult to separate “Colorectal” stats into Colon and Rectum
In USA 2019
• 44,180 new Rectal cancer cases
• 101,420 new Colon cancer cases
• Combined deaths 51,020
Confidential and proprietary. © ERS 2020. All rights reserved.
Rates are age adjusted to the
2000 US standard population
and are adjusted for reporting
delays.
Source: Incidence – SEER
Program, National Cancer
Institute, 2016. Mortality –
National Center for Health
Statistics, Centers for Disease
Control and Prevention, 2016.
©2017 American Cancer
Society, Inc., Surveillance
Research
6/11/2020
4
Rectal Cancer- History and Trends
Confidential and proprietary. © ERS 2020. All rights reserved.
Rectal Cancer Screening Recommendations
• Screening should be instigated at age 45 for average risk individuals
• Colonoscopy remains “Gold Standard”• Requires prep, typically includes sedation, most reliable screening
• Less invasive screening methods now available• CT Colonography
• Stool DNA test
• Guaiac-based fecal occult blood test (gFOBT)
• Fecal immunochemical test (FIT)
• If any yield abnormal results, colonoscopy still needs to be done
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
5
The future of screening?
Confidential and proprietary. © ERS 2020. All rights reserved.
Diagnosis of Rectal Cancer
• Non-symptomatic disease commonly dx by screening colonoscopy and polypectomy or biopsy
• Symptomatic disease also frequently leads to partial or full colonoscopy and either polypectomy or biopsy for diagnosis
• DRE- Somewhat primitive, somewhat controversial..
• Pathologic examination and tumor markers
• Histologic type and grade
• MSI/MMR- Indicators of Lynch Syndrome
• Genetic markers- KRAS, NRAS, BRAF
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
6
Rectal Cancer Markers
• MSI- Microsatellite Instability
• MMR or MMRP- Mis-Match Repair Proteins
• MLH1, MSH2, MSH6 and PMS2
• KRAS
• NRAS
• BRAF
• Her2
Confidential and proprietary. © ERS 2020. All rights reserved.
Rectal Cancer Surgery- Transanal
• Transanal Local Excision
• Small tumor (<3 cm)
• <30% circumferential
• Distal lesion (within 8 cm of anal verge)
• No LVI or PNI
• Well- Mod diff
• T1 only
• Full-thickness excision feasible
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
7
Diagnostic/ Staging- IMAGING
• MRI is preferred for
rectal/pelvic imaging
• Rectal EUS if not eligible for MRI
• CT or PET/CT of C/A/P
to rule out mets
Confidential and proprietary. © ERS 2020. All rights reserved.
This image reproduced for educational purposes with permission from the Radiology Assistant
Rectal MRI Synoptic Reports
• Standardized reporting for Rectal MRI
• NAPRC Standard 2.3-• For MRI staging to be effective, the technique of acquiring and interpreting the
images must be uniform and the results must be reported in a standardized report. Without standardized reporting, less than 40 percent of MRI reports contain all of the necessary information to make treatment decisions.
• Minimum elements to be included on report are defined in the Cancer Care Ontario template
• https://www.cancercareontario.ca/en/guidelines-advice/treatment-modality/surgery/quality-improvement-resources
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
8
Rectal MRI Standardized Report Template
Confidential and proprietary. © ERS 2020. All rights reserved.
Rectal Cancer Surgery
• New CoC standard for Total Mesorectal Excision (TME)
• CoC Standard 5.7 (phase-in)
• Applies to all Low and Mid rectal cancers treated with curative intent surgery
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
9
Rectal Cancer Surgery- Op Report
• NAPRC Standard for Surgical resection AND Synoptic Op reports
• Specialization of surgeons
• ASCRS rectal cancer checklist was used as a guide to developing the standardized synoptic Op report
• Minimum required elements are in Table 1 of NAPRC appendix
Confidential and proprietary. © ERS 2020. All rights reserved.
Confidential and proprietary. © ERS 2020. All rights reserved
6/11/2020
10
Announced Today 6/11/2020:
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standards- Chapter 1
• 1.1 - CoC accreditation
• 1.2 - Establish RCMDT• Physician disciplines include surgery, pathology,
radiology, medical onc and radiation onc
• 1.3 - Each member 50% attendance
• 1.4 - Meet twice each calendar month
• 1.5 - Appoint RCMDT director• Internal Audit Responsibilities
• Liaison between CoC and RCMDT
• Data Interpretation Responsibilities
• 1.6 - Appoint Program Coordinator
• 1.7 - Complete NAPRC Education
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
11
NAPRC Standards- Chapter 2
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standard 2.1
• The RCP must confirm the dx of rectal cancer before the initiation of tx at the accredited RCP
• If diagnosed elsewhere, RCP must review outside slides
• If slides cannot be obtained, reportsmust be reviewed
• If slides and reports are unavailable, the pt must be re-biopsied by the RCP
• Review of outside pathology must be documented in EMR
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
12
NAPRC Standard 2.2
• Previously untreated patients must have staging imaging
• Systemic staging with CT C/A/P or PET/CT C/A/P
• Local Staging with MRI of the pelvis• Exception for patients with documented contraindications to CT or MRI
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standard 2.3
• MRI with Rectal Protocol
• Uniformity in technique & interpretation
• Standardized Synoptic report
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
13
NAPRC Standard 2.4
• CEA level is obtained before definitive treatment begins
• Recorded in the EMR
• 75% compliance required
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standard 2.5Treatment planning discussion must include:
Review of diagnostic and staging studies
• Colonoscopy report (location of primary tumor and synchronous lesions) if present/available
• Biopsies of primary rectal cancer and metastases if present/available (Standard 2.1)
• CT scan or PET/CT of chest, abdomen, and pelvis (Standard 2.2)
• Rectal Cancer MRI (Standard 2.2)
• Pretreatment CEA level (Standard 2.4)
Assignment of clinical stage
• Clinical stage according to the AJCC
Creation of individualized treatment plan
• Neoadjuvant therapy regimen, when indicated
• Anticipated surgical procedure
• Referral to radiation oncology, when indicated
• Referral to medical oncology, when indicated
• Palliative care, when indicated
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
14
NAPRC Standard 2.6The physician who presents the patient to the RC-MDT is responsible for
ensuring communication and presentation of the evaluation and treatment
recommendation summary to the patient’s PCP and/or referring physician.
The standardized evaluation and treatment recommendation summary includes,
but is not limited to:
• Tumor location in the rectum
• Indication of sphincter involvement
• Pretreatment (clinical) AJCC stage
• Pretreatment CRM status
• CEA level
• Neoadjuvant therapy recommendation
• Type and duration of neoadjuvant therapy recommended
• Anticipated date and type of surgical procedure
• Clinical research study eligibility and/or enrollment
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standard 2.7
Accredited rectal cancer programs must ensure that 80 percent of previously untreated patients begin definitive treatment within 60 days of the patient’s initial clinical evaluation for rectal cancer at the accredited RCP. The treatment plan is documented in the patient’s medical record.
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
15
NAPRC Standard 2.8
• Specialized surgeons
• Members of the RC-MDT
• TME performed
• Standardized Op report
• Checklist fromNAPRC appendix1 is utilized
Confidential and proprietary. © ERS 2020. All rights reserved.
Photos from the free pages of the Operative Standards for Cancer Care downloaded from the CoC section of facs.org
NAPRC Standard 2.9
• Path reports must include all CAP Rectal Cancer Protocol elements• Includes an evaluation of the completeness of the mesorectal excision, the
status of the circumferential margin, and the response of the tumor to neoadjuvant therapy (Tumor Regression Grade)
• Standardized Synoptic format
• Path report complete within 2 weeks of the definitive surgicalresection
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
16
NAPRC Standard 2.10
• Minimum of 65 percent of rectal cancer specimens are photographed to document the quality of the mesorectum and include anterior, posterior, and lateral views.
• These images are shown and discussed at RC-MDT meetings and are electronically stored with a patient identifier.
• If the specimen is photographed but not presented and discussed at an RC-MDT meeting, then it does not qualify for the 65 percent required for compliance with this standard.
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standard 2.11
The four primary components of the
treatment outcome discussion* for
rectal cancer patients are:
1. Presurgical Evaluation and Treatment
2. Review of the outcome of the surgery
3. Review of the final pathology report and stage
4. Recommendation for adjuvant treatment
Confidential and proprietary. © ERS 2020. All rights reserved.
*The treatment outcome discussion
must happen within 4 weeks of the
patient’s definitive surgery, and the
discussion must be documented in the
EMR
6/11/2020
17
NAPRC Standard 2.12
The treatment summary must include, but is not limited to, the following information:
• Pretreatment (clinical) stage according to AJCC
• Pretreatment CEA level
• Neoadjuvant therapy before surgery
• Type of neoadjuvant therapy
• Neoadjuvant therapy date of completion
• Surgical procedure
• Date of surgery
• Final pathological stage according to AJCC
• Tumor Regression Grade
• Microsatellite instability status
• Circumferential Resection Margin
• Distal Resection Margin
• Mesorectal Grade
• Recommendation for adjuvant therapy (if applicable)
• Recommendation for adjuvant therapy regimen (if applicable)
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Standard 2.13
• NCCN Guidelines • Clinical or Pathologic Stage II and III
• 5-FU based systemic therapy
• Overall and disease free survival improved
• Initiate within 8 weeks after surgery• Document reasons for delays
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
18
NAPRC Chapter 3
Standard 3.1
• Submit all eligible rectal cancer cases to RQRS
• Submit within 3 months ofdiagnosis
Standard 3.2
• Review your program’s EPR (Estimated Performance Rate)
• Develop and execute plans for improving compliance
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Benefits
• Ensures specialized care for all Rectal Cancer Program patients
• Provides structure for treatment decisions through multidisciplinary discussions
• Provides timeline for milestones of care so delays are avoided
• Empowers patients through improved communication with Care Team
• Improves communication and accountability between Rectal Cancer Program members
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
19
NAPRC Data Collection
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Data Collection
Confidential and proprietary. © ERS 2020. All rights reserved.
Std 2.1
Std 2.2
Std 2.3
Std 2.4
6/11/2020
20
NAPRC Data Collection
Confidential and proprietary. © ERS 2020. All rights reserved.
Std 2.5
Std 2.6
Std 2.7
Std 2.8
Std 2.9
Std 2.10
Std 2.11
Std 2.12
Std 2.13
NAPRC Data Collection
• Five User-defined fields to capture further details or non-NAPRC standard info
• Text area to record information about treatment delays, or use as a tracking tool for upcoming due dates for treatment start, outcome discussion, etc.
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
21
NAPRC Registry Reporting
Confidential and proprietary. © ERS 2020. All rights reserved.
NAPRC Registry Reporting
Confidential and proprietary. © ERS 2020. All rights reserved.
6/11/2020
22
Thank you for participating!
Confidential and proprietary. © ERS 2020. All rights reserved.